{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T02:04:16Z","timestamp":1772503456473,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020473","name":"Australasian Paediatric Endocrine Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020473","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.bone.2022.116378","type":"journal-article","created":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T02:24:29Z","timestamp":1646447069000},"page":"116378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Combination treatment with growth hormone and zoledronic acid in a mouse model of Osteogenesis imperfecta"],"prefix":"10.1016","volume":"159","author":[{"given":"Lucinda R.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee E.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily R.","family":"Vasiljevski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra K.","family":"O'Donohue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tegan L.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Schindeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Biggin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig F.","family":"Munns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2022.116378_bb0005","first-page":"1","article-title":"Osteogenesis imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat.Rev. Dis. Prim."},{"key":"10.1016\/j.bone.2022.116378_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10174","article-title":"Osteogenesis imperfecta: new perspectives from clinical and translational research","volume":"3","author":"Tauer","year":"2019","journal-title":"JBMR Plus."},{"key":"10.1016\/j.bone.2022.116378_bb0015","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta","volume":"86","author":"\u00c5str\u00f6m","year":"2002","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.bone.2022.116378_bb0020","series-title":"Pediatrics","first-page":"S163","article-title":"Experience with bisphosphonates in osteogenesis imperfecta","author":"Glorieux","year":"2007"},{"key":"10.1016\/j.bone.2022.116378_bb0025","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s11914-017-0401-0","article-title":"Long-term bisphosphonate therapy in osteogenesis imperfecta","volume":"15","author":"Biggin","year":"2017","journal-title":"Curr. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2022.116378_bb0030","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic Administration of Pamidronate in children with severe osteogenesis imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2022.116378_bb0035","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116378_bb0040","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00005792-199707000-00005","article-title":"Long-term effects of bisphosphonates on the growing skeleton studies of young patients with severe osteoporosis","volume":"76","author":"Brumsen","year":"1997","journal-title":"Medicine"},{"key":"10.1016\/j.bone.2022.116378_bb0045","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","volume":"2016","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bone.2022.116378_bb0050","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials","volume":"30","author":"Hald","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116378_bb0055","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ajmg.1320450223","article-title":"Evaluation of growth hormone axis and responsiveness to growth stimulation of short children with osteogenesis imperfecta","volume":"45","author":"Marini","year":"1993","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.bone.2022.116378_bb0060","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0022-3476(96)70077-X","article-title":"Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis","volume":"129","author":"Antoniazzi","year":"1996","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bone.2022.116378_bb0065","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1359\/jbmr.2003.18.2.237","article-title":"Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: High predictive value of the carboxyterminal propeptide of type I procollagen","volume":"18","author":"Marini","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116378_bb0070","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1530\/EJE-10-0208","article-title":"GH in combination with bisphosphonate treatment in osteogenesis imperfecta","volume":"163","author":"Antoniazzi","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2022.116378_bb0075","first-page":"512","article-title":"Osteogenesis imperfecta: review of 40 patients","volume":"154","author":"Lafuente","year":"2020","journal-title":"Med. Clin. (Engl. Ed.)"},{"key":"10.1016\/j.bone.2022.116378_bb0080","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bone.2017.04.016","article-title":"Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta","volume":"101","author":"Little","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116378_bb0085","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1359\/JBMR.050108","article-title":"Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta","volume":"20","author":"King","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116378_bb0090","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bone.2022.116378_bb0095","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1359\/jbmr.090720","article-title":"Variable bone fragility associated with an Amish COL1A2 variant and a knock-in mouse model","volume":"25","author":"Daley","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116378_bb0100","series-title":"Developments in X-Ray Tomography VIII","article-title":"Drishti: a volume exploration and presentation tool","volume":"8506","author":"Limaye","year":"2012"},{"key":"10.1016\/j.bone.2022.116378_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep42505","article-title":"Quick and inexpensive paraffin-embedding method for dynamic bone formation analyses","volume":"7","author":"Porter","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bone.2022.116378_bb0110","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1359\/JBMR.050108","article-title":"Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta","volume":"20","author":"King","year":"2005","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2022.116378_bb0115","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/bonekey.2014.24","article-title":"Bisphosphonates and bone quality","volume":"3","author":"Pazianas","year":"2014","journal-title":"BoneKEy Rep."},{"key":"10.1016\/j.bone.2022.116378_bb0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.metabol.2017.06.001","article-title":"Osteogenesis imperfecta \u2013 a clinical update","volume":"80","author":"Tournis","year":"2018","journal-title":"Metab. Clin. Exp."},{"key":"10.1016\/j.bone.2022.116378_bb0125","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11914-018-0434-z","article-title":"Anabolic therapy for the treatment of osteoporosis in childhood","volume":"16","author":"Ward","year":"2018","journal-title":"Cur. Osteoporos. Rep."},{"key":"10.1016\/j.bone.2022.116378_bb0130","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1515\/jpem-2015-0385","article-title":"Children with severe Osteogenesis imperfecta and short stature present on average with normal IGF-I and IGFBP-3 levels","volume":"29","author":"Hoyer-Kuhn","year":"2016","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2022.116378_bb0135","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bone.2022.116378_bb0140","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bone.2015.03.016","article-title":"Mechanistic and therapeutic insights gained from studying rare skeletal diseases","volume":"76","author":"Tosi","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2022.116378_bb0145","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1203\/00006450-198303000-00007","article-title":"Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis irnperfecta tarda","volume":"17","author":"Baron","year":"1983","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.bone.2022.116378_bb0150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/dbio.2000.9975","article-title":"Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth","volume":"229","author":"Lupu","year":"2001","journal-title":"Dev. Biol."},{"key":"10.1016\/j.bone.2022.116378_bb0155","first-page":"368","article-title":"Zoledronic acid improves muscle function in healthy mice treated with chemotherapy","volume":"35","author":"Hain","year":"2020","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2022.116378_bb0160","first-page":"1","article-title":"Muscle abnormalities in osteogenesis imperfecta","volume":"17","author":"Veilleux","year":"2017"},{"key":"10.1016\/j.bone.2022.116378_bb0165","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1542\/peds.111.5.1030","article-title":"Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV","volume":"111","author":"Zeitlin","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.bone.2022.116378_bb0170","first-page":"987","article-title":"Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta","volume":"20","author":"King","year":"2005","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2022.116378_bb0175","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz149","article-title":"Long-acting growth hormone preparations - current status and future considerations","volume":"105","author":"Miller","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222000540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328222000540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:59:40Z","timestamp":1757613580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328222000540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":35,"alternative-id":["S8756328222000540"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2022.116378","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination treatment with growth hormone and zoledronic acid in a mouse model of Osteogenesis imperfecta","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2022.116378","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116378"}}